217. Outcomes of surgical treatment for patients with mild scoliosis and age appropriate sagittal alignment with minimum 2-year follow up

Abstract

BACKGROUND CONTEXT Operative treatment of adult spinal deformity (ASD) can be very challenging with high complication rates. Despite these challenges it's well established that pts benefit from such treatment. However, the surgical outcomes for pts with mild scoliosis and age appropriate sagittal alignment have not been reported. PURPOSE To determine if patients (pts) with mild scoliosis and age appropriate sagittal alignment have favorable outcomes following surgical correction. STUDY DESIGN/SETTING Retrospective review of a prospective, multicenter ASD database. PATIENT SAMPLE ASD patients: operative pts age≥18, and all preoperartive pelvic tilt (PT), mismatch between pelvic incidence and lumbar lordosis (PI-LL), and C7 sagittal vertical axis (SVA) within established age adjusted parameters with minimum 2-year follow up. A subanalysis for pts with max coronal cobb angle 10-30° (mild scoli) was done. OUTCOME MEASURES Health-related quality of life (HRQOL) scores: Oswestry Disability Index (ODI), Short form-36(SF36), Scoliosis Research Society (SRS22), back/leg pain numerical rating scale (NRS) and minimum clinically important difference (MCID)/substantial clinical benefit (SCB). Radiographic values: max coronal cobb angle, coronal C7 plumb line, PT, PI-LL, thoracic kyphosis (TK), SVA. Demographic, frailty, surgical and complications data were collected. METHODS Two-year and baseline HRQOL/radiographic data were compared. RESULTS A total of 103 pts were included from 667 operative patients (89.3% female, avg age 59.8±13.1yrs). Of the 103 pts, 29 (28.2%) had max preop coronal cobb angle 10-30°. Two-year max coronal cobb angle and C7 coronal plumb were significantly improved compared to baseline (p CONCLUSIONS Pts with mild scoliosis and sagittal alignment within age appropriate parameters benefit from surgical correction at 2 years postop both radiographically and clinically including 81.5% meeting MCID for SRS pain despite having high complication rates. FDA DEVICE/DRUG STATUS This abstract does not discuss or include any applicable devices or drugs.